Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Orelabrutinib in Hepatic Impairment
NCT05684653Phase 1Recruiting
- Sponsor
- InnoCare Pharma
- Start
- Mar 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of orelabrutinib in mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by InnoCare Pharma. Primary endpoints: Area under the concentration-time curve from time 0 to infinity at 48 hours, Area under the concentration-time curve from time 0 to infinity (AUC0-t) at 48 hours and 1 more. Started Mar 2023; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05684653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05684653.